过继性免疫化疗对小鼠和人非小细胞肺癌的治疗效应  

Antitumor Effect of Adoptive Immuno-chemotherapy on Non-small Cell Lung Cancer in Mice and Men

作　　者：郭坤元[1] 徐永康[1] 汪森明[1] 陈国强[1] 陆志刚[1] 冯永清[1] 沈淑华[1] 

机构地区：[1]第一军医大学珠江医院肿瘤科,广州510282

出　　处：《中国肿瘤生物治疗杂志》1994年第1期43-47,共5页Chinese Journal of Cancer Biotherapy

摘　　要：本文先给细胞毒化学药物,按序给LAK细胞与细胞因子,组成过继性免疫化疗方案。在C57BL/6J鼠体内显示,ADM与LAK有序联合应用对Lewis肺癌株在该鼠肺内瘤结节形成抑制率高达87％,明显高于单用LAK/IL-2的39％(P<0.05)或ADM的26％(P<0.01)。48例非小细胞肺癌治疗结果显示,单用MVP或CAP方案有效率为30％;单用LAK/IL-2有效率为33％,主要表现为对转移灶的治疗作用。而先给CAP或MVP化疗药,按序给LAK/IL-2有效率达69％(P<0.05),并有8％病例肿块消失完全缓解,且未增加副作用。两种方法有序结合,可能增加了对癌细胞亚群的杀伤强度与杀伤谱,因此过继性免疫化疗可作为治疗肺癌的新方案。Adoptive immuno-chemotherapy (AICT) protocol consisted of chemotherapy (CAP or MVP regimen) in combination with immunotherapy (LAK / IL-2 regimen) to treat the non-small cell lung cancer (NSCLC) in mice and men. In mice ADM in combination with LAK / IL-2 could obviously suppress the pulmonary nodule of Lewis lung cancer (LLC) line in C57BL/ 6J mice in vivo and the inhibition rate of ADM-LAK / IL-2 regimen to LLC pulmonary nodule was 87%, which was both higher than that of ADM regimen (26%, P<0.01) and LAK / IL-2 regimen (39%, P<0.05) respectively. In men, 48 cases of NSCLC patients were treated by the following three protocols. The responsive rate ( RR) of CAP or MVP chemotherapy protocol was 30% and the RR of LAK / IL-2 immunotherapy protocol was 33%. The RR of CAP or MVP in combination with LAK / IL-2 AICT protocol was 69%, which was higher than the RR of chemotherapy or immunotherapy protocol (P<0.05, ,P<0.05) .The complete rate (CR) of AICT protocol was 8% and no CR was seen in chemotherapy or immunotherapy protocol alone. AICT protocol appeared to be safe and tolerate in patients. AICT protocol may increase the killing intensity to the same tumor cells and can kill the tumor cells which were resistent to chemotherapeutic drugs. Antitumor effects of AICT protocol is better than that of chemoteherapy or immunotherapy protocol in NSCLC alone. A further study of AICT protocol is needed in the clinical treatment of the NSLLC as a novel one.

关 键 词：过继性免疫化疗 小鼠 人 非小细胞肺癌 治疗 

分 类 号：R734.2[医药卫生—肿瘤]